Gathering early perceptions of payer response to the Inflation Reduction Act of 2022: Medicare Part D Redesign
Unlock Key Insights into the IRA’s Medicare Part D Redesign
Magnolia Market Access (MMA) presents a detailed survey uncovering payer and manufacturer reactions to the Inflation Reduction Act’s Medicare Part D redesign. With insights from actuaries, medical directors, and pharmacy leaders covering 290 million+ lives, this report explores critical trends shaping the pharmaceutical landscape:
- Payer Strategies: How plans will intensify cost controls, including prior authorizations and formulary management, in response to $2,000 annual out-of-pocket caps.
- “Smoothing” Provisions: Insights on payers’ mixed responses to spreading costs over time to support beneficiary affordability.
- Impact on Premiums: Predictions for Medicare Part D premium adjustments, with expected increases ranging 4%–11% annually.
- Manufacturer Actions: Expectations of higher drug launch prices, reduced flexibility in rebate negotiations, and increased focus on outcomes-based contracts.
Download the full report to discover actionable insights, anticipate market shifts, and prepare for the IRA’s sweeping changes to drug access and affordability.
